Potassium dobesilate topical - DermAct Pharmaceutical

Drug Profile

Potassium dobesilate topical - DermAct Pharmaceutical

Alternative Names: AM-001

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DermAct Pharmaceutical
  • Developer AmDerma Pharmaceuticals; DermAct Pharmaceutical
  • Class Benzenesulfonates; Potassium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Plaque psoriasis

Most Recent Events

  • 12 Jun 2017 Phase-II clinical trials in Actinic keratosis in USA (Topical) (NCT03210740)
  • 23 Jan 2017 Chemical structure information added
  • 02 Jan 2017 No development reported - Phase-II for Plaque psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top